Joslin research boosts evidence for a new class of treatments to help preserve vision in people with diabetes, including diabetic macular edema and retinopathy.
FDA Expands the Approved Use for Lucentis to Treat Diabetic Retinopathy in Patients with Diabetic Macular Edema
Diabetic retinopathy is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects more than 29 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2008, 33 percent of adults with diabetes aged 40 years or older had some form of DR. In some cases of DR with DME, abnormal new blood vessels grow on the surface of the retina. Severe vision loss or blindness can occur if the new blood vessels break.